Research & Awards
The gut microbiome is one of the most promising areas of science today. Researchers are currently inivestigating how to manipulate the gut microbiome to treat disease and improve human health.
New AGA clinical guideline: The role of probiotics in the management of gastrointestinal disorders
After conducting a detailed review of available literature, AGA has released new clinical guidelines finding that for most digestive conditions there is not enough evidence to support the use of probiotics.
Check out our four-part CME series titled, “The Microbiome and Digestive Health: Look at Prebiotics.” This educational activity is supported by an educational grant from GlaxoSmithKline.
The AGA Center for Gut Microbiome Research and Education responds to new probiotics research.
Dr. Purna Kashyap breaks down what the literature tells us about probiotics, and how to best answer patient questions on the topic.
Understanding mechanisms is important to develop personalized interventions for maintaining health or treating disease. Ece A. Mutlu, MD, MBA, AGAF, provides an overview of current knowledge on this topic.
When it comes to therapeutic implications of the gut microbiome, the currently available pre-, pro- and synbiotics only represent the tip of the iceberg.
Share these resources with your patients to help them understand probiotics: what they do, who they are right for, how to choose them, and safety information.
AGA leaders recently traveled to FDA headquarters to
have a candid conversation about FMT regulation.
Visit AGA University to access the slides presented as part of the 2018 Crohn’s and Colitis Congress pre-workshop on fecal microbiota transplantation (FMT).
Colleen Kelly, MD, provides an update on the use of fecal microbiota transplantation (FMT) in clinical practice.
Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies
In CGH, Dr. Colleen R. Kelly and colleagues provide guidance to researchers on the preparation and submission of investigational new drug (IND) applications to study FMT.
In Gastroenterology, Dr. Colleen R. Kelly and colleagues discuss indications, methodologies, mechanisms and outlook on fecal microbiota transplantation (FMT).
Provide this hand-out/link to your patients to help them understand FMT as a treatment option for recurring C. difficile infection.
Follow these guidelines to properly code and bill private payors and Medicare for fecal microbiota transplant (FMT).
Alexander Khoruts, MD, provides his insights on the rationale behind microbiome-based diagnostics and whether the currently available tests have clinical utility.
Dr. Rob Knight and colleagues provide insight into the different techniques for assaying the microbiome via DNA sequencing.
Rob Knight, PhD, and Embriette R. Hyde, PhD, update us on what they uncovered from the second installment of the AGA-American Gut Project GI stool analysis.
Recent trials have demonstrated that specific probiotics can alter brain connectivity in healthy individuals. Dr. Premysl Bercik shares evidence of the gut microbiota’s role in the gut-brain axis.
Dr. Jasmohan Bajaj highlights three key articles advancing our understanding of the interplay between liver disorders and the gut microbiome.
Chathur Acharya, MD, and Jasmohan S. Bajaj, MD, AGAF, discuss the microbiome-gut-liver- brain axis and its role in the pathogenesis of hepatic encephalopathy (HE).
Brought to you by the